Bone-seeking radiopharmaceuticals in patients with skeletal metastases. Clinical experience using alpha-emitting radium-223

被引：0
|
作者：
Nilsson, S.
Larsen, R. H.
Bruland, O. S.
机构：
[1] Karolinska Hosp, S-10401 Stockholm, Sweden
[2] Algeta ASA, Oslo, Norway
[3] Norwegian Radium Hosp, Oslo, Norway
来源：
RADIOTHERAPY AND ONCOLOGY | 2006年 / 78卷
关键词：
D O I：
10.1016/S0167-8140(06)80562-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [41] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer
    Oliveira-Silva, Catherine C.
    Maillard, Mateus S.
    Silva, Raoni
    Sa, Lidia, V
    PHYSICS IN MEDICINE AND BIOLOGY, 2024, 69 (20):
  • [44] Bone scintigraphy to evaluate response to therapy with Radium-223 for castration-resistant prostate cancer patients with bone metastases: a single-center experience
    Martinez Albero, E.
    Gomez Grande, A.
    Saviatto Nardi, A.
    Galiana Moron, A.
    Vega Perez, D.
    Godigna Guilloteau, V.
    Pilkington Woll, J.
    Ruiz Solis, S.
    Sarandeses Fernandez, P.
    Tabuenca Mateo, M.
    Estenoz Alfaro, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S696 - S696
  • [45] Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases
    Volkova, M., I
    Olshanskaya, A. S.
    ONKOUROLOGIYA, 2019, 15 (02): : 134 - 142
  • [46] Initial post-approval clinical experience with Radium-223 dichloride in patients with prostate cancer
    Conti, Peter
    Challa, Sudha
    Jadvar, Hossein
    Pinski, Jacek
    Gross, Mitchell
    Dorff, Tanya
    Quinn, David
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [47] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [48] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [49] Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review
    Cursano, M. C.
    Iuliani, M.
    Casadei, C.
    Stellato, M.
    Tonini, G.
    Paganelli, G.
    Santini, D.
    De Giorgi, U.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [50] Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy
    Wenter, Vera
    Herlemann, Annika
    Fendler, Wolfgang P.
    Ilhan, Harun
    Tirichter, Natalia
    Bartenstein, Peter
    Stief, Christian G.
    la Fougere, Christian
    Albert, Nathalie L.
    Rominger, Axel
    Gratzke, Christian
    ONCOTARGET, 2017, 8 (27) : 44131 - 44140
12345